![]() |
Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019 | ![]() |
Monday, 04. November 2019 22:30 | ||||
---|---|---|---|---|
CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and a Q&A session related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual congress in San Diego, California. Webcast Details:
To access the live webcasts, please go to the Investors section of Biogen’s website at investors.biogen.com. Following the live webcasts, archived versions will be available on the website. About Biogen We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube. About Aducanumab EMERGE and ENGAGE were Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate the efficacy and safety of aducanumab. The primary objective of the studies was to evaluate the efficacy of monthly doses of aducanumab as compared with placebo in reducing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score. Secondary objectives were to assess the effect of monthly doses of aducanumab as compared to placebo on clinical decline as measured by the Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 Items (ADAS-Cog 13), and the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory Mild Cognitive Impairment Version (ADCS-ADL-MCI).
|
||||
Related Links: Biogen Inc. | ||||
Author: Copyright GlobeNewswire, Inc. 2016. All rights reserved. You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account. |